Open Journal of Nursing, 2020, 10, 617-635
https://www.scirp.org/journal/ojn
Antimicrobial Resistance and Infection Control 2014,3 :31
Rev Esp Sanid Penit 2012; 14: 11-16 11
The document will provide information for Ministries of Health and hospital sentinel sites on why and how to determine the denominator of at-risk children <5 years of age and rate of meningitis hospitalizations for a sentinel hospital site conducting IB-VPD surveillance. Such a methodology is curren...tly unavailable and this estimation is critical to enable interpretation of surveillance data, particularly pre- and post- vaccine introduction
more
The Interim Guidance for Risk Communication and Community Engagement (RCCE) outlines recommendations, considerations and methods to raise awareness, manage risk perception, maintain trust and proactively support people at risk to make informed decisions to protect themselves and others from monkeypo...x. The guidance includes recommendations on identifying and communicating with affected populations and key audiences and avoiding stigma in communications outreach. It also includes key messages about symptoms of monkeypox, transmission, prevention measures, and communicating about uncertainty. This document also provides RCCE guidance for managers and planners of gatherings and events, where close physical contact may create an environment conducive for the transmission of monkeypox. Additionally, this document includes a compendium of recommendations for RCCE methods and resources to support the monkeypox response.
more
Recommendations on the inclusion of people with disabilities in eye care made by CBM's Medical Eye Care Advisory Group as a result of
a meeting in Hydrabad, India, in 2012.
African Journal of Laboratory Medicine | Vol 7, No 2 | a796 | 06 December 2018
Lancet Psychiatry 2016;3: 415–24
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more
Case Study
Accessed: 30.10.2019
Weekly epidemiological update on COVID-19, 28 September 2022
A lack of knowledge about the threat of vaccine-preventable diseases, risks and benefits of vaccines, mistrust of government and health workers, poor service delivery and alternative health or religious beliefs play a role in lower uptake of some vaccines. These challenges underscore the importance ...of early integration and investment in a thoughtful communication plan for immunization programmes. This World Health Organization (WHO) report presents communication guidance and specific considerations for countries that plan to introduce human papillomavirus (HPV) vaccine into their national immunisation programme as part of an effort to prevent cervical cancer.
more
This paper, originally presented as a Sussex Development Lecture, asks how the Ebola crisis might offer a lens to reflect on interlaced challenges around curbing inequalities, accelerating sustainability, and building inclusive, secure societies, and why these matter so much. And it discusses why ad...dressing these interactions must become central to a renewed vision of development for all
more